Can Borrelia serology alone prove active infection or neurologic causation?

The claim is substantially supported: Borrelia serology must be interpreted as evidence of immune exposure within a compatible clinical and diagnostic context, not as proof of ongoing infection or neurologic causation.

Clinical and diagnostic evidence

• Borrelia-specific IgM and IgG can persist for months, years, or potentially decades after infection has resolved or been eradicated. A positive result may therefore reflect remote exposure, prior treated infection, or durable immune memory rather than viable organisms.
• False-positive seroreactivity can occur with other spirochetal infections, Epstein–Barr virus, rheumatoid arthritis, and other autoimmune or infectious conditions. Isolated IgM is particularly problematic after 30 days of illness, when CDC guidance advises disregarding it.
• For suspected Lyme neuroborreliosis, serum positivity alone is insufficient. Definite disease frameworks require a compatible neurologic syndrome, cerebrospinal-fluid (CSF) pleocytosis, and intrathecal Borrelia-specific antibody production; CSF lymphocytic/monocytic inflammation supports active CNS involvement. PCR and culture may occasionally support early disease but have limited routine sensitivity.

Mechanistic findings

• Molecular mimicry is biologically plausible but not established as a common clinical mechanism. Experimental work identifies shared antigenic determinants between Borrelia flagellin and neural tissue; flagellin-directed monoclonal antibodies have recognized peripheral nerve fibers, CNS neurons, and an axonal HSP60-related epitope, with altered neurite growth in cultured cells.
• These observations demonstrate potential neural-antigen recognition, not that such antibodies commonly arise in patients or cause in-vivo neurologic injury. Neuronal autoantibodies are not commonly detected in neuroborreliosis, and binding or sequence similarity alone does not establish pathogenic autoimmunity.

Bottom line

• Positive Borrelia serology without a compatible objective syndrome and corroborating evidence does not establish active infection or explain neurologic disease. Molecular mimicry remains a plausible experimental hypothesis, but it should not substitute for clinical, CSF, and—where appropriate—targeted microbiologic evaluation.